Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
iShares U.S. Pharmaceuticals ETF IHE
$178.49
-$1.26 (-0.70%)
На 18:01, 12 мая 2023
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
197.28
-
week52low
166.99
-
Revenue
-
P/E TTM
-
Beta
0.00000000
-
EPS
10.11485400
-
Last Dividend
3.61100000
-
Next Earnings Date
07 мая 2023 г. в 02:21
Описание компании
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Pharma ETFs Gain Post Q1 Earnings
Zacks Investment Research
09 мая 2023 г. в 13:01
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
IHE: Pharmaceutical Stocks Are Cheap And Offer High Long-Term Returns
Seeking Alpha
02 мая 2023 г. в 00:03
IHE invests in U.S. pharmaceutical stocks. Based on consensus forward earnings growth estimates, IHE looks undervalued.
ETFs to Buy on Solid Q1 JNJ Earnings Results
Zacks Investment Research
19 апр 2023 г. в 12:56
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Zacks Investment Research
20 мар 2023 г. в 07:42
Sector ETF report for IHE
IHE: A Top-Heavy Pharma ETF That's More Average Than Outstanding
Seeking Alpha
02 февр 2023 г. в 18:07
IHE tracks the Dow Jones U.S. Select Pharmaceuticals Total Return Index, which invests solely in U.S. pharmaceutical companies. The fund is top-heavy, investing around 40% in just two companies: Johnson & Johnson and Eli Lilly.